Exploring the role of senescence inducers and senotherapeutics as targets for anticancer natural products

Abdullah Al Mamun, Mohammad Abu Sufian, Md. Sahab Uddin, Dewan Md Sumsuzzman, Philippe Jeandet, Mohammad Safiqul Islam, Hong Jie Zhang, Ah Ng Kong, Md. Shahid Sarwar*

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

10 Citations (Scopus)


During the last few decades, cancer has remained one of the deadliest diseases that endanger human health, emphasizing urgent drug discovery. Cellular senescence has gained a great deal of attention in recent years because of its link to the development of cancer therapy. Senescent cells are incapable of proliferating due to irreversibly inhibition of the initiation of the cell cycle pathways. However, senescent cells aggregate in tissues and produce a pro-inflammatory secretome called senescence-associated secretory phenotype (SASP) that can cause serious harmful effects if not managed properly. There is mounting evidence that senescent cells lead to various phases of tumorigenesis in various anatomical sites, owing mostly to the paracrine activities of the SASP. Therefore, a new treatment field called senotherapeutics has been established. Senotherapeutics are newly developed anticancer agents that have been demonstrated to inhibit cancer efficiently. In light of recent findings, several promising natural products have been identified as senescence inducers and senotherapeutics, including, miliusanes, epigallocatechin gallate, phloretin, silybin, resveratrol, genistein, sulforaphane, quercetin, allicin, fisetin, piperlongumine, berberine, triptolide, tocotrienols and curcumin analogs. Some of them have already been validated through preclinical trials and exert an enormous potential for clinical trials. This review article focuses on and summarizes the latest advances made on cellular senescence and its potential as a target for cancer treatment and highlights the well-known natural products as senescence inducers and senotherapeutics for cancer treatment.

Original languageEnglish
Article number174991
JournalEuropean Journal of Pharmacology
Early online date2 May 2022
Publication statusPublished - 5 Aug 2022

Scopus Subject Areas

  • Pharmacology

User-Defined Keywords

  • Cancer
  • Cellular senescence
  • Natural products
  • Senolytic agents
  • Senotherapeutics


Dive into the research topics of 'Exploring the role of senescence inducers and senotherapeutics as targets for anticancer natural products'. Together they form a unique fingerprint.

Cite this